CD59 blockade enhances antigen-specific CD4+ T cell responses in humans: A new target for cancer Immunotherapy?

Journal of Immunology

Volumn 182, Issue 9, 2009, Pages 5203-5207

  Sivasankar, Baalasubramanian ^a   Longhi, M Paula ^a,b   Gallagher, Kathleen M E ^a   Betts, Gareth J ^a   Morgan, B Paul ^a   Godkin, Andrew J ^a   Gallimore, Awen M ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; CD59 PROTEIN, HUMAN; EPITOPE; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CANCER PATIENT; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; UPREGULATION; ADOPTIVE IMMUNOTHERAPY; CELL STRAIN U937; COLORECTAL TUMOR; CYTOLOGY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY;

ANTIGENS, CD59; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; COLORECTAL NEOPLASMS; EPITOPES, T-LYMPHOCYTE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; U937 CELLS; UP-REGULATION;

EID: 66949117099     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0804243     Document Type: Article

References (13)

1. Kimberley, F. C., B. Sivasankar, and B. Paul Morgan. 2007. Alternative roles for CD59. Mol. Immunol. 44: 73-81.
2. Korty, P. E., C. Brando, and E. M. Shevach. 1991. CD59 functions as a signal-transducing molecule for human T cell activation. J. Immunol. 146: 4092-4098.
3. + T cell activity in a complement-independent manner. J. Immunol. 175: 7098-7102.
4. Longhi, M. P., A. Williams, M. Wise, B. P. Morgan, and A. Gallimore. 2007. CD59a deficiency exacerbates influenza-induced lung inflammation through complement-dependent and -independent mechanisms. Eur. J. Immunol. 37: 1266-1274.
5. Bodian, D. L., S. J. Davis, B. P. Morgan, and N. K. Rushmere. 1997. Mutational analysis of the active site and antibody epitopes of the complement-inhibitory glycoprotein, CD59. J. Exp. Med. 185: 507-516.
6. + regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS ONE 1: e129.
7. Baalasubramanian, S., C. L. Harris, R. M. Donev, M. Mizuno, N. Omidvar, W. C. Song, and B. P. Morgan. 2004. CD59a is the primary regulator of membrane attack complex assembly in the mouse. J. Immunol. 173: 3684-3692. (Pubitemid 39280729)
8. + regulatory T cells by antigen-processing dendritic cells. J. Exp. Med. 198: 235-247.
9. Thompson, J. A., F. Grunert, and W. Zimmermann. 1991. Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J. Clin. Lab. Anal. 5: 344-366.
10. Woods, A. M., W. W. Wang, D. M. Shaw, C. M. Ward, M. W. Carroll, B. R. Rees, and P. L. Stern. 2002. Characterization of the murine 5T4 oncofoetal antigen: a target for immunotherapy in cancer. Biochem. J. 366: 353-365. (Pubitemid 34971836)
11. Christmas, S., C. de la Mata Espinosa, D. Halliday, C. Buxton, J. Cummerson, and P. Johnson. 2006. Levels of expression of complement regulatory proteins CD46, CD55 and CD59 on resting and activated human peripheral blood leucocytes. Immunology 119: 522-528. (Pubitemid 44722215)
12. Rosenberg, S. A., N. P. Restifo, J. C. Yang, R. A. Morgan, and M. E. Dudley. 2008. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 8: 299-308.
13. + T cells against NY-ESO-1. N. Engl. J. Med. 358: 2698-2703.